Notably, clinical evidence suggests that GLP-1 receptor agonists exhibit stronger efficacy than SGLT2 inhibitors in reducing atherosclerosis-related cardiovascular events, such as myocardial infarction and stroke [157]. Here, SLC5A2 is linked to stroke disorder.